Combined inhibition of HER2 and VEGFR synergistically improves therapeutic efficacy via PI3K-AKT pathway in advanced ovarian cancer

被引：0
|
作者：
Weisong Li
Kai Zhang
Wenjun Wang
Yuanyuan Liu
Jianming Huang
Meihong Zheng
Ling Li
Xinyu Zhang
Minjuan Xu
Guofang Chen
Liefeng Wang
Shuyong Zhang
机构：
[1] First Affiliated Hospital,Department of Pathology
[2] Gannan Medical University,Key Laboratory of Prevention and Treatment of Cardiovascular and Cerebrovascular Diseases (Ministry of Education)
[3] Gannan Medical University,School of Basic Medicine
[4] Gannan Medical University,Department of Immunology, School of Basic Medical Sciences
[5] Fudan University,Department of Gynaecology and Obstetrics
[6] Ganzhou People’s Hospital (The Affiliated Ganzhou Hospital of Nanchang University),Shanghai Key Laboratory of Maternal Fetal Medicine, Clinical and Translational Research Center, Shanghai First Maternity and Infant Hospital, School of Medicine
[7] Shanghai Institute of Maternal-Fetal Medicine and Gynecologic Oncology,undefined
[8] Tongji University,undefined
来源：
Journal of Experimental & Clinical Cancer Research | / 43卷
关键词：
HER2; VEGFR; Antibody drug conjugate; RC48; Cediranib Maleate; Synergetic effect; Ovarian cancer;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [1] Combined inhibition of HER2 and VEGFR synergistically improves therapeutic efficacy via PI3K-AKT pathway in advanced ovarian cancer
    Li, Weisong
    Zhang, Kai
    Wang, Wenjun
    Liu, Yuanyuan
    Huang, Jianming
    Zheng, Meihong
    Li, Ling
    Zhang, Xinyu
    Xu, Minjuan
    Chen, Guofang
    Wang, Liefeng
    Zhang, Shuyong
    JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH, 2024, 43 (01)
  • [2] HER2 Expression and PI3K-Akt Pathway Alterations in Gastric Cancer
    Sukawa, Yasutaka
    Yamamoto, Hiroyuki
    Nosho, Katsuhiko
    Ito, Miki
    Igarashi, Hisayoshi
    Naito, Takafumi
    Mitsuhashi, Kei
    Matsunaga, Yasutaka
    Takahashi, Taiga
    Mikami, Masashi
    Adachi, Yasushi
    Suzuki, Hiromu
    Shinomura, Yasuhisa
    DIGESTION, 2014, 89 (01) : 12 - 17
  • [3] Hyperactivation of the PI3K-AKT Pathway Commonly Underlies Resistance to Trastuzumab in HER2 Amplified Breast Cancer
    Chandarlapaty, S.
    King, T.
    Sakr, R.
    Barbashina, V
    Arroyo, N.
    Morrogh, M.
    Wynveen, C.
    Shanu, M.
    Norton, L.
    Rosen, N.
    Hudis, C.
    CANCER RESEARCH, 2009, 69 (24) : 526S - 527S
  • [4] Inhibition of PI3K pathway improves anti HER2 treatment efficacy in a panel of HER2 positive gastric cancer cell lines
    Gambardella, V.
    Llorca-Cardenosa, M. J.
    Castillo, J.
    Tarazona Llavero, N.
    Huerta, M.
    Rosello Keranen, S.
    Ibarolla-Villava, M.
    Ribas, G.
    Gil, A.
    Cervantes, A.
    ANNALS OF ONCOLOGY, 2016, 27
  • [5] The immune impact of PI3K-AKT pathway inhibition in colorectal cancer
    Nusrat, Maliha
    Syed, Muddassir Ali
    Katkhuda, Riham
    Parra, Edwin R.
    Wistuba, Ignacio Ivan
    Kong, Paul
    Koehne, Amanda
    Dasari, Arvind
    Overman, Michael J.
    Menter, David
    Kopetz, Scott
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (04)
  • [6] Combined PI3K-AKT and MEK-ERK pathway inhibition provides broad antitumor efficacy in HER2+breast tumor models
    De, Pradip
    Sun, Yuliang
    Carlson, Jennifer
    Friedman, Lori
    Dey, Nandini
    Leyland-Jones, Brian
    CANCER RESEARCH, 2014, 74 (19)
  • [7] Downregulation of HER2 by RIG1 involves the PI3K/Akt pathway in ovarian cancer cells
    Ou, Chien-Chih
    Hsu, Shih-Chung
    Hsieh, Yin-Hui
    Tsou, Wan-Ling
    Chuang, Tzu-Chao
    Liu, Jah-Yao
    Kao, Ming-Ching
    CARCINOGENESIS, 2008, 29 (02) : 299 - 306
  • [8] HER2/PI3K/AKT pathway in HER2-positive breast cancer: A review
    Pan, Linghui
    Li, Jinling
    Xu, Qi
    Gao, Zili
    Yang, Mao
    Wu, Xiaoping
    Li, Xuesen
    MEDICINE, 2024, 103 (24) : e38508
  • [9] The antiproliferative effect of quercetin in cancer cells is mediated via inhibition of the PI3K-Akt/PKB pathway
    Gulati, N
    Laudet, B
    Zohrabian, VM
    Murali, R
    Jhanwar-Uniyal, M
    ANTICANCER RESEARCH, 2006, 26 (2A) : 1177 - 1181
  • [10] CTCFL regulates the PI3K-Akt pathway and it is a target for personalized ovarian cancer therapy
    Marisol Salgado-Albarrán
    Julian Späth
    Rodrigo González-Barrios
    Jan Baumbach
    Ernesto Soto-Reyes
    npj Systems Biology and Applications, 8
12345